Relmacabtagene autoleucel

JW Discloses CARTEYVA Reimbursement Price

JW Therapeutics disclosed a RMB288,600 National Reimbursement Drug List price for relmacabtagene autoleucel, effective 1 January 2027, covering three lymphoma indications. This product-level price is new information beyond China’s 14 November list announcement. Access…